INSIGHTS ON CLINICAL TRIAL DESIGN
-
Analyzing The FDA's Approach To Diversity In Clinical Trials
Learn how utilizing diverse data resources and collaborating with stakeholders enables sponsors to foster a culture of inclusivity, meet regulatory requirements and ultimately advance medical science.
-
Reducing The Burden Of Patient Retention And Improving Continuity
Immunology trials often place a sustained burden on participants. However, integrating Home Trial Support (HTS) into a Phase 3 immunology trial can help improve the overall study experience.
-
The Phase 2 Endpoint Dilemma
Phase 2 neuro endpoints can miss subtle change. Learn when composites help or hinder, how to align cognition, function, and biomarkers with real-world data for go/no-go decisions.
-
Advanced Strategies For Faster, More Effective Recruitment
Modern patient-first enrollment strategies are combining digital outreach with data-driven targeting and protocol-specific screeners to identify eligible patients while reducing site burden.
-
Keeping Your Trials In Motion And Use AI Where It Makes Sense2/2/2026
Explore the "pinball" approach used by the Judi platform that is giving stakeholders a distinct competitive advantage in the clinical trial landscape.
-
Advancing Clinical Research In 2025: Meeting FDA Standards In DCT1/22/2025
Explore the key components of new FDA guidance on DCTs, including a focus on participant-centric designs and the use of Mobile Research Units (MRUs) to overcome geographic and technological barriers.
-
Advancing Alzheimer's Disease Therapies9/3/2025
By uniting scientific innovation with patient-focused execution, the next generation of alzheimer’s disease (AD) therapies has the potential to deliver a transformative impact on global health.
-
Where Study Simulation Fits In Clinical Trials4/21/2026
Simulation lets teams test assumptions early, showing how design and operations affect timelines, cost, and feasibility — reducing risk and enabling confident, data‑driven decisions.
-
A Framework For Selecting Reliable Clinical Endpoints From Real-World DHT Data2/25/2025
Dr. Andy Liu presents a case study determining which digital measure of physical activity would be a well-defined and reliable clinical endpoint in a trial including patients with diabetes.
CLINICAL TRIAL DESIGN SOLUTIONS
-
At Endpoint Clinical, our solutions proactively problem-solve. We expect the unexpected, so you can focus on reaching key clinical trial milestones.
-
With over 60 HAP studies successfully conducted in the last decade, Altasciences has experience in diverse areas such as for stimulants, opioids, and sedative-hypnotics.
-
AutoCruitment's patient recruitment services have assisted with 700+ trials in more than 38 countries. Looking for patients with over 120 different conditions, they have enrolled 14600+ patients and achieved a 97% increase in randomization.
-
Delve into the details of our Patient Navigator services, which are designed to eliminate patients’ barriers to clinical trial participation and maximize study outcomes through patient experience.
-
Metabolic and endocrine diseases are a rising therapy area focus for clinical research due to the high demand for novel therapies that are challenged with proving safety and efficacy.